阿法替尼治疗肺癌的临床疗效与安全性

Clinical research progress of afatinib therapy for lung cancer

阿法替尼是第二代口服小分子酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI),适用于晚期非小细胞肺癌(non-small-celllungcancer,NSCLC)一线治疗和鳞状NSCLC的二线治疗。目前,大量有力的临床研究数据已证实了阿法替尼的疗效和安全性。因此,本文就阿法替尼的药物作用机制、药动学特点临床疗效、联合用药、不良反应及剂量调整等方面进行综述,以期为阿法替尼个体化合理用药指导提供思路。

Afatinib,a second-generation oral tyrosine kinase inhibitor(TKI),is suitable for first-line treatment of advanced non-small-cell lung cancer(NSCLC)and second-line treatment of squamous NSCLC.At present,a large number of strong clinical research data has confirmed the efficacy and safety of afatinib.Therefore,this article reviews the mechanism of action,pharmacokinetic clinical efficacy,combination of drugs,adverse reactions and dose adjustment of afatinib in order to provide ideas for individual rational drug use guidance.